Page 2 - பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் கனடா இணை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் கனடா இணை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் கனடா இணை Today - Breaking & Trending Today

Federal Court Upholds Patent Validity And Issues Declarations Of Infringement Against Two Generic Apixaban Tablets - Intellectual Property

Canadian Patent No. 2,461,202 (the
202
Patent), which was asserted by Bristol-Myers Squibb Canada
Co. and Bristol-Myers Squibb Holdings Ireland Unlimited Company
(collectively,
BMS). The 202 Patent claims
the active ingredient apixaban and its use for the treatment and
prevention of thromboembolic disorders (blood clots).
Canadian Patent No. 2,791,171 (the
171
Patent), which was asserted by BMS and Pfizer Inc.
(collectively,
BMS & Pfizer). The 171
Patent claims tablet formulations of apixaban.
The Defendants only non-infringement allegation was that
the asserted claims of each of the patents were invalid.
The 202 Patent: compound and use claims valid and
infringed
Construction. The sole issue with respect
to construction of the asserted claims of the 202 Patent was ....

United States , Norton Rose Fulbright , Sandoz Canada Inc , Pharmascience Inc , Pfizer Inc , Bristol Myers Squibb Canada Co , Norton Rose Fulbright Canada , Bristol Myers Squibb Holdings Ireland Unlimited Company , Federal Court , Bristol Myers Squibb Canada , Sandoz Canada , Patented Medicines , Rose Fulbright , Latin America , Federal Court Upholds Patent Validity And Issues Declarations Of Infringement Against Two Generic Apixaban Tablets , Intellectual Property , ஒன்றுபட்டது மாநிலங்களில் , நார்டன் உயர்ந்தது ஃபுல்பிரைட் , சாண்டோஸ் கனடா இன்க் , ஃபைசர் இன்க் , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் கனடா இணை , நார்டன் உயர்ந்தது ஃபுல்பிரைட் கனடா , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் ஹோல்டிங்ஸ் ஐயர்ல்யாஂட் வரம்பற்ற நிறுவனம் , கூட்டாட்சியின் நீதிமன்றம் , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் கனடா , சாண்டோஸ் கனடா ,

Health Canada Approves ONUREG® (azacitidine tablets), First Maintenance Therapy for Patients in Remission from Acute Myeloid Leukemia

Learn more about Acute Myeloid Leukemia and ONUREG (CNW Group/Bristol Myers Squibb Canada Co.)
AML is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone marrow failure, and is the most common form of acute leukemia in adults, accounting for approximately 80 per cent of adult cases.
2,3,4 An estimated 40-60 per cent of patients aged 60 years and older and 60-80 per cent of patients under 60 years old will obtain complete remission through induction chemotherapy (IC); however, 50 per cent will relapse within a year.
5,6 Once a relapse occurs, long-term survival averages at six months.
7 In 2015, an estimated 1,235 Canadians were diagnosed with AML and the overall incidence rate in Canada is 3.46/100,000 people. ....

Alannah Nugent , Andre Schuh , Rachel Yates , Garzon Rj Clin , Bristol Myers Squibb , Al Reba , Bristol Myers Squibb Canada Co , Princess Margaret Cancer Centre , Public Health , Bristol Myers Squibb Company , Leukemia Lymphoma Society Of Canada , Health Canada , Corporate Affairs , General Manager , Myers Squibb Canada , Myers Squibb , Product Monograph , Clin Med , Lymphoma Society , Acute Myeloid , Accessed December , Bristol Myers Squibb Canada , Account Executive , Health Care Amp Hospitals , Medical Pharmaceuticals , International Medical Approval ,